



# Elucidate Bio Announces Joint Poster Presentation with IN8bio at ISCT 2026

*Joint ISCT 2026 poster highlights spatial multi-omic analysis of GBM patients treated with  $\gamma\delta$  T cell therapy, revealing tumor microenvironment insights.*

MEDFORD, MA, UNITED STATES, May 6, 2026 /EINPresswire.com/ -- Elucidate Bio, Inc., an AI-enabled biomarker discovery company, today announced an upcoming joint poster presentation with IN8bio, Inc. (Nasdaq: INAB) at the International Society for Cell & Gene Therapy (ISCT) 2026 Annual Meeting.

Details for the ISCT 2026 presentation are as follows:

Title: Unraveling Complexity: The Impact, Interactions and Outcomes of a  $\gamma\delta$  T Cell Therapy in Glioblastoma

Presenters: Mariska A. ter Haak, Catherine P. Langford, Gulpreet Kaur, James Perna, Jason L. Weirather, Lawrence Lamb, Kate M. Rochlin

Abstract #: 1283

Session: Poster Reception #2 - Immunotherapy (CAR-T, T Reg, NK Cells etc.)

Date and Time: Thursday, May 7, 2026, 6:00 – 7:30 PM GMT

The poster presents spatial multi-omic characterization of glioblastoma (GBM) tumor microenvironment sections from patients treated with IN8bio's DeltEx DRI  $\gamma\delta$  T cell therapy or SOC using the Elucidate Discovery Engine.

## About Elucidate Bio

Elucidate Bio is an AI-driven biomarker discovery partner for precision medicine. Its Synoptic Tumor Mapping approach integrates proteomic, transcriptomic, genomic, and morphologic data from the same tissue slide to deliver a unified view of the tumor-immune microenvironment. Powered by [ELUCID](#), its proprietary AI Pathologist, Elucidate Bio enables biopharma partners to uncover mechanisms of action, identify predictive biomarkers, and stratify patients for clinical success. For more information, visit [elucidatebio.com](https://elucidatebio.com). Follow on [LinkedIn](#).

## About IN8bio

IN8bio is a clinical-stage biopharmaceutical company developing  $\gamma\delta$  T cell and  $\gamma\delta$  T cell engager (TCE) product candidates to address unmet medical needs.  $\gamma\delta$  T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company's pipeline is anchored by INB-600, a novel  $\gamma\delta$  T cell engager

platform with potential applications across oncology and autoimmune indications. IN8bio is also advancing INB-100, an allogeneic  $\gamma\delta$  T cell candidate for adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation, and INB-200/400, an autologous genetically modified  $\gamma\delta$  T cell candidate for newly diagnosed glioblastoma (GBM). For more information about IN8bio, visit [www.IN8bio.com](http://www.IN8bio.com).

Elucidate Bio Contact:

Gulpreet Kaur

Chief Business Officer, Elucidate Bio

[gulpreet@elucidatebio.com](mailto:gulpreet@elucidatebio.com)

IN8 Bio contact:

IN8bio, Inc.

Patrick McCall

646.933.5603

[pfmccall@IN8bio.com](mailto:pfmccall@IN8bio.com)

Gulpreet Kaur

Elucidate Bio

[gulpreet@elucidatebio.com](mailto:gulpreet@elucidatebio.com)

Visit us on social media:

[LinkedIn](#)

[X](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/910633463>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2026 Newsmatics Inc. All Right Reserved.